Together, these preliminary results open the door for a tDCS-based symptomatic management of numerous motor disorders
Indirect network meta-analyses rank retatrutide highly, but that is cross-trial inference, not a direct win
Key dates Information webinar: 6 July 2026, 15:00 to 17:00 CEST Stage 0, Expression of Interest (mandatory): 1 July to 10 September 2026 Stage 1, Short Proposal: 15 September to 29 October 2026 Full details of the ECTC 2026 are available on the ERDERA call page, including the pre-announcement of the call, the official call text and application documents published at the launch on 1 July
Im very pleased with the service of VITAstir
This is where the conversation gets really interesting
Maintenance phase: settle at the lowest dose that delivers the desired effect